Galderma Group Valuation
Is GALDZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GALDZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GALDZ (CHF88.53) is trading below our estimate of fair value (CHF176.65)
Significantly Below Fair Value: GALDZ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GALDZ?
Key metric: As GALDZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is GALDZ's PS Ratio? | |
|---|---|
| PS Ratio | 5.5x |
| Sales | US$4.32b |
| Market Cap | US$23.62b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.1x |
| Enterprise Value/EBITDA | 31.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GALDZ's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.6x | ||
GSK GSK | 1.8x | 3.9% | UK£54.9b |
DPH Dechra Pharmaceuticals | 5.8x | 7.9% | UK£4.4b |
HIK Hikma Pharmaceuticals | 1.8x | 4.4% | UK£4.4b |
HCM HUTCHMED (China) | 5x | 18.0% | UK£2.4b |
GALDZ Galderma Group | 5.5x | 11.6% | CHF 21.0b |
Price-To-Sales vs Peers: GALDZ is expensive based on its Price-To-Sales Ratio (5.5x) compared to the peer average (3.6x).
Price to Sales Ratio vs Industry
How does GALDZ's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
EAH ECO Animal Health Group | 0.5x | 5.9% | US$54.43m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: GALDZ is expensive based on its Price-To-Sales Ratio (5.5x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is GALDZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.5x |
| Fair PS Ratio | 6.5x |
Price-To-Sales vs Fair Ratio: GALDZ is good value based on its Price-To-Sales Ratio (5.5x) compared to the estimated Fair Price-To-Sales Ratio (6.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 88.53 | CHF 93.19 +5.3% | 7.5% | CHF 107.68 | CHF 80.47 | n/a | 11 |
| Nov ’25 | CHF 81.66 | CHF 89.50 +9.6% | 8.0% | CHF 105.87 | CHF 79.12 | n/a | 11 |
| Oct ’25 | CHF 77.56 | CHF 82.53 +6.4% | 9.5% | CHF 102.40 | CHF 72.86 | n/a | 11 |
| Sep ’25 | CHF 82.67 | CHF 79.93 -3.3% | 7.6% | CHF 90.06 | CHF 70.28 | n/a | 10 |
| Aug ’25 | CHF 69.55 | CHF 77.33 +11.2% | 5.0% | CHF 82.41 | CHF 71.02 | n/a | 8 |
| Jul ’25 | CHF 72.05 | CHF 78.75 +9.3% | 4.8% | CHF 83.81 | CHF 70.73 | n/a | 8 |
| Jun ’25 | CHF 73.54 | CHF 78.21 +6.4% | 4.3% | CHF 81.95 | CHF 71.43 | n/a | 7 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Formycon
€848.4m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.50
7D
4.3%
1Y
-21.3%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€63.05
7D
1.3%
1Y
13.6%
Regeneron Pharmaceuticals
US$79.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$745.13
7D
-2.1%
1Y
-6.5%